Strategic Hiring Dunad Therapeutics has recently bolstered leadership with a new Chief Medical Officer in February 2026, signaling elevated clinical development ambition and potential for expanding collaborations with pharma/biotech partners seeking clinical execution strength.

Clinical Partnerships Active participation in industry events and a pipeline highlighted by proteomics-based drug discovery presentations present opportunities to engage for co-development, advisory roles, or sponsored research collaborations with CROs and biotech firms focused on protein degradation and targeted therapies.

Expansion Signals Past leadership additions in business development and scientific roles, plus ongoing research activities, imply readiness for partner-led programs, licensing conversations, or milestone-driven collaborations to accelerate discovery and translation.

Early Revenue Potential Current revenue range suggests a small-to-mid biotech profile with appetite for milestone-rich deals, including upfronts, research funding, and co-development arrangements with larger biologics and biotech companies seeking innovation in covalent chemistry and disease-targeted therapies.

Technology & IP Focus Dunad’s emphasis on proprietary tunable covalent chemistry and disease biology offers a compelling value proposition for collaboration on target engagement platforms, assay development, and translational research partnerships that align with biotech and CROs seeking differentiated modalities.